MetaCap

Compass Therapeutics Earnings

NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.6882+0.0097 (+1.43%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Compass Therapeutics earnings summary

In its most recent report on Nov 9, 2026 (Sep/2026), CMPX posted EPS of $-0.15 versus the $-0.12 consensus estimate, a negative surprise of 25.0%. Compass Therapeutics beat the consensus EPS estimate in 1 of the last 2 quarters, with a median surprise of +4.2%. Across the last 16 reports, CMPX shares moved an average of 8.9% (in either direction) in the first trading session after results, rising 12 times and falling 4 times.

Summary generated from market data by MetaCap's automated system. Methodology

CMPX earnings history

Compass Therapeutics reported EPS versus estimates
Report dateEPS est.EPS actualSurprisePrice reaction
Nov 9, 2026$-0.12$-0.15-25.0%-11.1%
Nov 4, 2026$-0.12$-0.08+33.3%+2.0%
Aug 6, 2026—$-0.13—+4.7%
May 5, 2026—$-0.10—+1.6%
Jan 6, 2026—$-0.08—+6.5%
Nov 5, 2025—$-0.08—+14.2%
Aug 11, 2025—$-0.14—+1.7%
May 8, 2025—$-0.12—+15.4%
Jan 8, 2025—$-0.10—+46.9%
Nov 12, 2024—$-0.08—+8.0%
Aug 12, 2024—$-0.10—+8.6%
May 13, 2024—$-0.08—-8.1%
Mar 21, 2024—$-0.10—-7.0%
Nov 9, 2023—$-0.08—+2.6%
Aug 3, 2023—$-0.09—+3.2%
May 4, 2023—$-0.06—-1.7%

Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.

Related